WO2003070174A3 - Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof - Google Patents
Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof Download PDFInfo
- Publication number
- WO2003070174A3 WO2003070174A3 PCT/US2003/004609 US0304609W WO03070174A3 WO 2003070174 A3 WO2003070174 A3 WO 2003070174A3 US 0304609 W US0304609 W US 0304609W WO 03070174 A3 WO03070174 A3 WO 03070174A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugates
- formulation
- preparation
- methods
- transportophore
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 230000001937 non-anti-biotic effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/504,787 US20050171342A1 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
EP03716044A EP1483277A4 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
NZ535354A NZ535354A (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
IL16355203A IL163552A0 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
AU2003219770A AU2003219770B2 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
CA002476423A CA2476423A1 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
IL163552A IL163552A (en) | 2002-02-15 | 2004-08-15 | Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same |
HR20040850A HRP20040850A2 (en) | 2002-02-15 | 2004-09-15 | Conjugates of biologically active compounds, methods for their preparation and use formulation and pharmaceutical applications thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35743402P | 2002-02-15 | 2002-02-15 | |
US60/357,434 | 2002-02-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003070174A2 WO2003070174A2 (en) | 2003-08-28 |
WO2003070174A3 true WO2003070174A3 (en) | 2003-11-13 |
Family
ID=27757618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/004609 WO2003070174A2 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US7579324B2 (en) |
EP (1) | EP1483277A4 (en) |
AU (1) | AU2003219770B2 (en) |
CA (1) | CA2476423A1 (en) |
HR (1) | HRP20040850A2 (en) |
IL (1) | IL163552A (en) |
NZ (1) | NZ535354A (en) |
WO (1) | WO2003070174A2 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3945985B2 (en) * | 2000-12-28 | 2007-07-18 | 株式会社リコー | Digital camera device |
HRP20010018A2 (en) | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
KR20040066788A (en) | 2001-08-31 | 2004-07-27 | 더 락커펠러 유니버시티 | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
EP1483579A4 (en) * | 2002-02-15 | 2006-07-12 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
WO2003070254A1 (en) * | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Antibiotic conjugates |
ATE429441T1 (en) | 2002-07-08 | 2009-05-15 | Glaxosmithkline Zagreb | HYBRID MOLECULES OF MACROLIDS WITH STEROIDAL/NON-STEROIDAL ANTI-INFLAMMATORY ACTIVE MOLECULES |
US7091187B2 (en) | 2002-07-08 | 2006-08-15 | Pliva-Istrazivacki Institut D.O.O. | Compounds, compositions and methods for treatment of inflammatory diseases and conditions |
BR0312584A (en) | 2002-07-08 | 2005-04-12 | Pliva Istrazivacki Inst D O O | New non-steroidal anti-inflammatory substances, compounds and methods for their use |
TW200420573A (en) | 2002-09-26 | 2004-10-16 | Rib X Pharmaceuticals Inc | Bifunctional heterocyclic compounds and methods of making and using same |
HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
EP1682563A1 (en) * | 2003-10-30 | 2006-07-26 | Rib-X Pharmaceuticals, Inc. | Bifunctional macrolide heterocyclic compounds and mehtods of making and using the same |
WO2005049632A1 (en) * | 2003-11-18 | 2005-06-02 | Rib-X Pharmaceuticals, Inc. | Bifunctional macrolide heterocyclic compounds and methods of making and using the same |
US8202843B2 (en) | 2004-02-27 | 2012-06-19 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
KR20070046917A (en) * | 2004-08-12 | 2007-05-03 | 글락소스미쓰클라인 이스트라지바치키 센타 자그레브 디.오.오. | Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
US20060183696A1 (en) * | 2004-08-12 | 2006-08-17 | Pliva-Istrazivacki Institut D.O.O. | Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract |
US7767797B1 (en) | 2004-09-30 | 2010-08-03 | Synovo Gmbh | Macrocyclic compounds and methods of use thereof |
GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
AU2005298312A1 (en) | 2004-10-27 | 2006-05-04 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Conjugates with anti-inflammatory activity |
EP1846428A1 (en) * | 2005-01-14 | 2007-10-24 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Anti-inflammatory conjugates of macrolides and coumarins |
JP5084725B2 (en) | 2005-06-06 | 2012-11-28 | 武田薬品工業株式会社 | Organic compounds |
WO2007012464A1 (en) * | 2005-07-26 | 2007-02-01 | Merckle Gmbh | Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase |
AU2006272496B2 (en) * | 2005-07-27 | 2013-03-07 | University Of Southern California | Coumarin-based amino acids for use in enzyme activity and substrate specificity assays |
EP1919287A4 (en) * | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | Organic compounds for treating reduced dopamine receptor signalling activity |
JP5126685B2 (en) | 2006-05-01 | 2013-01-23 | 大正製薬株式会社 | Macrolide derivatives |
EP2081431B1 (en) * | 2006-11-13 | 2013-01-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | Novel uses |
US20110281812A1 (en) * | 2009-01-30 | 2011-11-17 | Sulejman Alihodzic | Compounds |
WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2461673A4 (en) | 2009-08-05 | 2013-08-07 | Intra Cellular Therapies Inc | Novel regulatory proteins and inhibitors |
AU2011313862A1 (en) * | 2010-10-10 | 2013-05-30 | Synovo Gmbh | Anti-inflammatory macrolides |
WO2013148874A1 (en) | 2012-03-27 | 2013-10-03 | Burnet Michael W | Anti-inflammatory macrolides |
DK2849567T3 (en) | 2012-05-17 | 2022-06-20 | Extend Biosciences Inc | CARRIERS FOR IMPROVED MEDICINE ADMINISTRATION |
JP6549040B2 (en) | 2013-02-17 | 2019-07-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | New use |
EP3479825B1 (en) | 2013-03-15 | 2021-02-17 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders |
US9073936B2 (en) | 2013-03-15 | 2015-07-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9884872B2 (en) | 2014-06-20 | 2018-02-06 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
RU2711442C2 (en) | 2014-09-17 | 2020-01-17 | Интра-Селлулар Терапиз, Инк. | Compounds and methods |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
EP3220961B1 (en) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
GB201520419D0 (en) | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
JP7401442B2 (en) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | new use |
JP2022529315A (en) | 2019-04-18 | 2022-06-21 | アズーラ オフサルミックス エルティーディー. | Compounds and methods for treating eye disorders |
WO2023248010A2 (en) | 2022-06-23 | 2023-12-28 | Synovo Gmbh | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
US6562796B2 (en) * | 2000-01-14 | 2003-05-13 | Micrologix Biotech Inc. | Derivatives of polyene macrolides and preparation and use thereof |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3417077A (en) * | 1966-05-16 | 1968-12-17 | Lilly Co Eli | Erythromycin derivative and process for the preparation thereof |
US4375414A (en) * | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US3884903A (en) * | 1973-06-21 | 1975-05-20 | Abbott Lab | 4{41 -Deoxy-4{41 -oxoerythromycin B derivatives |
EP0009944B1 (en) | 1978-10-02 | 1983-05-18 | Merck & Co. Inc. | Lysosomotropic fluorinated amine therapeutic agents and compositions containing them |
YU43116B (en) * | 1979-04-02 | 1989-04-30 | Pliva Pharm & Chem Works | Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox |
SI8110592A8 (en) * | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
US4382086A (en) * | 1982-03-01 | 1983-05-03 | Pfizer Inc. | 9-Dihydro-11,12-ketal derivatives of erythromycin A and epi-erythromycin A |
US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
US4518590A (en) | 1984-04-13 | 1985-05-21 | Pfizer Inc. | 9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method |
US4585759A (en) | 1985-01-22 | 1986-04-29 | Pfizer Inc. | Antibacterial derivatives of a neutral macrolide |
JPH0720857B2 (en) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
US5466681A (en) * | 1990-02-23 | 1995-11-14 | Microcarb, Inc. | Receptor conjugates for targeting penicillin antibiotics to bacteria |
US5405975A (en) * | 1993-03-29 | 1995-04-11 | Molecular Probes, Inc. | Fluorescent ion-selective diaryldiaza crown ether conjugates |
SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
JPH07103148B2 (en) | 1991-12-16 | 1995-11-08 | 株式会社ディ・ディ・エス研究所 | Anthracycline-macrolide complex |
US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5486536A (en) * | 1994-08-15 | 1996-01-23 | The Regents Of The University Of Michigan | Sulfatides as anti-inflammatory compounds |
FR2738571B1 (en) * | 1995-09-11 | 1997-10-17 | Roussel Uclaf | NOVEL DERIVATIVES OF 5-0-DESOSAMINYL 6-0-METHYL- ERYTHRONOLIDE A, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO THE PREPARATION OF BIOLOGICALLY ACTIVE PRODUCTS |
JP2000508923A (en) * | 1996-04-26 | 2000-07-18 | マサチューセッツ・インスティテュート・オブ・テクノロジー | 3-Hybrid screening assay |
WO1998029437A2 (en) | 1996-12-30 | 1998-07-09 | Governors Of The University Of Alberta | Mammalian equilibrative nucleoside transporters |
US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
EP0895999A1 (en) | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
KR100554549B1 (en) | 1997-10-16 | 2006-03-03 | 플리바 파마세우츠카 인두스트리야, 디오닉코, 드러스트보 | NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES |
HRP980189B1 (en) | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
CA2318547A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Combinatorial synthesis of multibinding libraries |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
AU4549999A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Novel polyene macrolide compounds and uses |
US6043227A (en) | 1998-08-19 | 2000-03-28 | Pfizer Inc. | C11 carbamates of macrolide antibacterials |
US6100240A (en) | 1998-10-09 | 2000-08-08 | Pfizer Inc | Macrolide derivatives |
EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
EP1212619B1 (en) | 1999-09-14 | 2007-05-23 | Xenoport, Inc. | Substrates and screening methods for transport proteins |
ID27331A (en) | 1999-09-29 | 2001-03-29 | Pfizer Prod Inc | MAKING ANTIBIOTIC-ANTIBIOTIC KETOLIDA CARBAMATE |
EP1122261A3 (en) | 2000-01-31 | 2001-09-26 | Pfizer Products Inc. | 13 and 14-membered antibacterial macrolides |
ES2222966T3 (en) | 2000-06-30 | 2005-02-16 | Pfizer Products Inc. | ANTIBIOTIC MACROLIDS. |
HRP20010018A2 (en) * | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
EP1453837A4 (en) | 2001-11-21 | 2007-11-07 | Activbiotics Inc | Targeted therapeutics and uses thereof |
WO2003070254A1 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Antibiotic conjugates |
EP1483579A4 (en) | 2002-02-15 | 2006-07-12 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
US7091187B2 (en) * | 2002-07-08 | 2006-08-15 | Pliva-Istrazivacki Institut D.O.O. | Compounds, compositions and methods for treatment of inflammatory diseases and conditions |
-
2003
- 2003-02-14 WO PCT/US2003/004609 patent/WO2003070174A2/en not_active Application Discontinuation
- 2003-02-14 NZ NZ535354A patent/NZ535354A/en unknown
- 2003-02-14 CA CA002476423A patent/CA2476423A1/en not_active Abandoned
- 2003-02-14 AU AU2003219770A patent/AU2003219770B2/en not_active Ceased
- 2003-02-14 US US10/367,105 patent/US7579324B2/en not_active Expired - Fee Related
- 2003-02-14 EP EP03716044A patent/EP1483277A4/en not_active Withdrawn
- 2003-02-14 US US10/504,787 patent/US20050171342A1/en not_active Abandoned
-
2004
- 2004-08-15 IL IL163552A patent/IL163552A/en not_active IP Right Cessation
- 2004-09-15 HR HR20040850A patent/HRP20040850A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
US6562796B2 (en) * | 2000-01-14 | 2003-05-13 | Micrologix Biotech Inc. | Derivatives of polyene macrolides and preparation and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1483277A2 (en) | 2004-12-08 |
US20040087517A1 (en) | 2004-05-06 |
WO2003070174A2 (en) | 2003-08-28 |
US7579324B2 (en) | 2009-08-25 |
AU2003219770B2 (en) | 2008-10-09 |
AU2003219770A1 (en) | 2003-09-09 |
US20050171342A1 (en) | 2005-08-04 |
NZ535354A (en) | 2008-01-31 |
EP1483277A4 (en) | 2007-10-03 |
IL163552A (en) | 2010-11-30 |
HRP20040850A2 (en) | 2005-08-31 |
CA2476423A1 (en) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003070174A3 (en) | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | |
KR100581443B1 (en) | Drug Composites | |
CN102516417B (en) | Cyclodextrin-based polymers for therapeutics delivery | |
WO2003061577A3 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
EP3100719A3 (en) | Delivery of nucleic acid-like compounds | |
WO2005028516A3 (en) | Albumin-binding derivatives of therapeutic peptides | |
WO2003028527A3 (en) | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof | |
BR0008590A (en) | Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed | |
WO2002024715A3 (en) | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers | |
CA2439500A1 (en) | Drug delivery system for hydrophobic drugs | |
EP2253333A3 (en) | Contrast Agents for Myocardial Perfusion Imaging | |
TWI315203B (en) | Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments | |
WO2005027828A3 (en) | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | |
WO2002088172A3 (en) | Pentapeptide compounds and uses related thereto | |
AU6011701A (en) | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same | |
WO2007060104A3 (en) | Aerosol formulation for inhalation containing an anticholinergic agent | |
WO2009150284A3 (en) | Apo-a conjugates for the administration of biologically active compounds | |
AU2003215245A8 (en) | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | |
WO2001092283A3 (en) | Cobalamin compounds useful as cardiovascular agents and as imaging agents | |
WO2007060408A3 (en) | L-phenylalanine derivatives and their use as integrin antagonists | |
WO1999024076A3 (en) | Salicylate derivatized therapeutic and diagnostic agents | |
EP1666459A3 (en) | Aminocyclohexyl ether compounds and uses thereof | |
WO2014180533A2 (en) | Conjugates for protection from nephrotoxic active substances | |
TW200634002A (en) | Chemical compounds | |
WO2004112838A3 (en) | Codrugs of diclofenac |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1815/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163552 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2476423 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003219770 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20040850A Country of ref document: HR Ref document number: 535354 Country of ref document: NZ Ref document number: 2003716044 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003716044 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10504787 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |